|
Press Releases |
|
|
|
Wednesday, September 15, 2021 |
|
Hua and Sinopharm Announced Supply Chain Strategic Cooperation |
On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099). more info >> |
|
Thursday, August 19, 2021 |
|
华领医药公布2021年中期业绩 |
华领医药(「公司」,香港联交所股份代号:2552.HK),今天宣布公司及其附属公司截至2021年6月30日止,6个月(「报告期」)的综合业绩。 more info >> |
|
華領醫藥公佈2021年中期業績 |
華領醫藥(「公司」,香港聯交所股份代號:2552.HK),今天宣佈公司及其附屬公司截至2021年6月30日止,6個月(「報告期」)的綜合業績。 more info >> |
|
Hua Medicine Announces 2021 Interim Results |
Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period"). more info >> |
|
Friday, April 23, 2021 |
|
华领医药糖尿病首创新药多扎格列艾汀NDA获NMPA受理!为全球首个葡萄糖激酶激活剂 |
华领医药(「公司」,香港联交所股份代号:2552.HK),今天宣布,糖尿病首创新药多扎格列艾汀( dorzagliatin)递交的NDA申请已获国家药品监督管理局(NMPA)新药审评中心(CDE)受理。多扎格列艾汀成为全球范围内首个提交新药上市申请的葡萄糖激酶激活剂类(GKA)糖尿病治疗药物,并有望成为在中国首先上市的全球首创新药(FIC)。 more info >> |
|
華領醫藥糖尿病首創新藥多扎格列艾汀NDA獲NMPA受理!為全球首個葡萄糖激酶激活劑 |
華領醫藥(「公司」,香港聯交所股份代號:2552.HK),今天宣布,糖尿病首創新藥多扎格列艾汀(dorzagliatin)遞交的NDA申請已獲國家藥品監督管理局(NMPA)新藥審評中心(CDE)受理。 more info >> |
|
Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally |
Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). more info >> |
|
Friday, March 19, 2021 |
|
华领医药公布2020年全年业绩 |
华领医药(「公司」,香港联交所股份代号:2552.HK),今天宣布公司及其附属公司截至2020年12月31日止经审核的全年业绩(「报告期」)。 more info >> |
|
華領醫藥公佈2020年全年業績 |
華領醫藥(「公司」,香港聯交所股份代號:2552.HK),今天宣佈公司及其附屬公司截至2020年12月31日止經審核的全年業績(「報告期」)。 more info >> |
|
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission |
Hua Medicine (2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Fujitsu drives chemical industry logistics DX with participation in joint logistics demonstration
Dec 23, 2024 13:30 JST
|
|
|
中國核電榮膺中國證券「金紫荊獎」兩項大獎
Dec 23, 2024 12:24 HKT/SGT
|
|
|
広汽Hondaの開発区新エネルギー車工場が稼働開始
Dec 23, 2024 11:30: JST
|
|
|
吳佩慈男友紀曉波發聲明 否認參與緬甸「恒升園區」
Dec 23, 2024 11:29 HKT/SGT
|
|
|
吴佩慈男友纪晓波发声明 否认参与缅甸「恒升园区」
Dec 23, 2024 11:27 HKT/SGT
|
|
|
Seamless HDB Renovations: How 2 Design Combines Expertise with In-House Solutions
Dec 23, 2024 11:00: JST
|
|
|
富士通など、モダナイゼーションに特化したファイナンスサービスを提供開始
Dec 23, 2024 10:30: JST
|
|
|
Seamless HDB Renovations: How 2 Design Combines Expertise with In-House Solutions
Dec 23, 2024 10:00 HKT/SGT
|
|
|
Summit Group Responds to White Paper Citing Governance Issues in Bangladesh's Power and Energy Sector
Dec 23, 2024 09:00 HKT/SGT
|
|
|
TechGALA 2025 - 愛知縣首屆國際初創企業大會
Dec 23, 2024 08:00 HKT/SGT
|
|
|
The finest places to live, work, and thrive in Asia are celebrated at the 19th PropertyGuru Asia Property Awards Grand Final
Dec 23, 2024 07:50 HKT/SGT
|
|
|
Mainland China, Hong Kong, Macau companies triumph at finale of 2024 PropertyGuru Asia Property Awards
Dec 22, 2024 20:50 HKT/SGT
|
|
|
The 2024 PropertyGuru Asia Property Awards International Luncheon celebrates real estate achievements in the Middle East and South Asia
Dec 22, 2024 19:30 HKT/SGT
|
|
|
Virturo Elite Club: Unlock Exclusive Wealth-Building Opportunities for High-Net-Worth Individuals
Dec 21, 2024 09:30: JST
|
|
|
Pathwizz Redefines Trust in Digital Transactions with Award-Winning Support and Verified Platforms 'Wizz Support'
Dec 21, 2024 09:00: JST
|
|
|
|
More News >> |
|
|
|
|
|